Combination therapy for pulmonary fibrosis may be an option
KEY POINT
Combination therapy with nintedanib (Ofev—Boehringer Ingelheim) and pirfenidone (Esbriet—Genentech) for patients with idiopathic pulmonary fibrosis (IPF) was found to be adequately tolerated, according to results of the INJOURNEY trial published in the American Journal of Respiratory and Critical Care Medicine.
SOURCES
Vancheri C, et al. Nintedanib with add-on pirfenidone in idiopathic pulmonary fibrosis: Results of the INJOURNEY trial. Am J Respir Crit Care Med. 2018;197(3):356–63.
